SANBS begins research on convalescent plasma for treatment of Covid-19

December 2019 will always be remembered as a month where the novel coronavirus disease (Covid-19) started its worldwide spread. As we sit amidst the international pandemic, the SARS-CoV-2 infection continues to claim lives with the numbers of infections increasing exponentially every day.

Within the South African context, swift responses have allowed the country to contain a rapid spread of the virus.
The rollout of a proactive diagnostic programme, isolation and quarantine have all proved effective supportive measures to limit the spread, yet there remains no cure for Covid-19.
There is an international rush to develop vaccines and treatment options for the illness and effective treatments are crucial for curing patients.

As a cornerstone of the healthcare fraternity in South Africa, the South African National Blood Service (SANBS) and the Western Cape Blood Service (WCBS) are exploring ways to use blood plasma for the treatment of Covid-19 patients locally. Research forms a large part of their operations and following the recent approval from the Human Research Ethics Committee they will, in the next few weeks, start collecting convalescent plasma from patients who have recovered from Covid-19. This convalescent plasma will be used in Phase 2 clinical trials to confirm whether this therapy will benefit patients admitted to hospitals with pneumonia caused by the virus. It is noteworthy that the treatment will primarily be in the experimental phase, with the rollout being a priority.
Convalescent plasma, plasma collected from patients who have recovered from a viral infection, has long been used as a way to treat patients still critically ill from the same viral infection. This plasma contains neutralising antibodies and provides passive immunity to an infected patient. It significantly improves their clinical status and often helps them to recover quicker. It has not yet been widely used in the South African context. Such therapy was explored in West-Africa to treat patients with the Ebola Virus. Before that, it was successfully used to treat SARS-CoV and MERS-CoV. The development of Covid-19 antibody treatments will, however, take several months to complete.
The SANBS intends to start collecting convalescent plasma from donors who have fully recovered from Covid-19. To be eligible to donate, 28 days must have elapsed since the patients last exhibited symptoms of infection.

This gives the patient time to develop sufficient antibodies to be therapeutic and fully recover from the disease. It also minimises the risk of such patients still being able to transmit the virus.
Initially, these plasma products will only be issued in patients participating in SAHPRA approved Phase 2 clinical trials.

While there are still no specific medi- cations approved to treat Covid-19, work has commenced worldwide on convalescent plasma harvested from people who have recovered from the infection.
The SANBS is uniquely positioned to both collect and collaborate in clinical trials of convalescent plasma that will subsequently be used in patients hospitalised with Covid-19, in the hope that it will reduce mortality and result in quicker recovery.